LTR Pharma stretches ED treatment reach through major pharmacy chain

LTR Pharma’s nasal spray for erectile dysfunction treatment SPONTAN is now available through the TerryWhite Chemmart national pharmacy network.

LTR Pharma is expanding reach of its ED treatment nationwide. Pic: via Getty Images.

• LTR Pharma’s SPONTAN erectile dysfunction spray available through the TerryWhite Chemmart network nationwide

• New barcoded commercial packaging developed to support pharmacy integration and telehealth pathways

• Patients with prescriptions from healthcare professionals can now have them filled at participating pharmacies across Australia

 

Special Report:  LTR Pharma has announced that its nasal spray-mist erectile dysfunction (ED) treatment SPONTAN is now available through the extensive TerryWhite Chemmart (TWC) national pharmacy network.

LTR Pharma (ASX: LTP) said the achievement marks a significant step in LTR Pharma’s strategy to expand patient access to SPONTAN, following its distribution partnership with Symbion announced in January.

TWC is a subsidiary of pharmacy distributor EBOS Group (ASX:EBO) alongside Symbion, operating one of the country's largest pharmacy networks with more than 600 locations across Australia including a strong presence in metropolitan and regional areas.

LTR Pharma said SPONTAN’s availability through the TWC network represents a pivotal milestone in its access and readiness strategy for the ED treatment, which is transitioning from limited availability to broader pharmacy availability under regulated pathways.

Patients with a prescription for SPONTAN from an authorised healthcare professional can now have their prescriptions filled at any participating TerryWhite Chemmart, Pharmacy Choice, or healthSAVE pharmacies.

Dispensing of the ED treatment  is carried out by registered healthcare professionals in accordance with the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS).

Commercial packaging for SPONTAN

LTR Pharma now has new commercial packaging for SPONTAN, which has been designed specifically for pharmacy distribution.

The company said the packaging incorporates TGA compliant labelling, patient information materials, and pharmacy-standard barcodes.

LTR Pharma and Symbion have completed all key integration milestones in their distribution agreement, including:

• Integration of inventory management systems
• Implementation of TGA-compliant tracking protocols
• Establishment of product handling procedures
• Completion of pharmacist education and training materials

LTR Pharma will present an education class at the TWC Masterclass in June, informing pharmacists across the network with clinical insights and dispensing guidance for SPONTAN under the SAS and APS.

Chance to gather real-world data

LTR said the expanded pharmacy rollout enables the company to gather valuable real-world data on SPONTAN usage.

This data will support the company’s regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia and the US launch of Roxus in 2026, providing insights into prescribing patterns, patient experience and market dynamics.

Roxus is LTR Pharma’s new ED nasal spray targeting the US personalised healthcare sector.

"The national rollout of SPONTAN through TerryWhite Chemmart and other pharmacy networks represents the implementation of our Symbion partnership and delivers convenient physical access points for patients across the country,” LTR Pharma executive chairman Lee Rodne said.

“This milestone supports our commitment to improving the availability of SPONTAN across Australia while we progress our regulatory pathway.

“Patients can now have their SPONTAN prescriptions filled at participating pharmacies nationwide, providing a direct pathway from healthcare professional to pharmacy dispensing."

This article was developed in collaboration LTR Pharma, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.